Νέα

The recent population movement has led to a steady increase of carriers and patients with haemoglobin disorders, namely thalassaemia and sickle cell disease, in all countries of the European Union.…

The European Medicines Agency (EMA)’s safety committee (PRAC) has concluded that there is no evidence Zynteglo causes a blood cancer known as acute myeloid leukaemia (AML). Zynteglo, a gene therapy…

The past decade has witnessed path-breaking advances with regard to novel therapeutic approaches of thalassaemia and, most significantly, phenomenal developments made in the direction of gene therapy of β- thalassaemia…

TIF provides you with comprehensive and up-to-date information on developing drugs and therapies for thalassaemia and sickle cell disease (SCD) currently in clinical trials. Our most recent June 2021 update…

In response to the invitation of the Prime Minister’s Advisors Authority to Mr. Thaer Ibrahim Al-Taei, President of the Thalassemia Society in Niniva (NTS), Iraq, and Dr. Madin Mohamed Fawzy,…

As vaccination rates are slowing in the US and Europe, the spread of the Delta coronavirus variants causes growing concerns worldwide with health experts predicting the highly infectious variant to…

TIF, its Board of Directors, and its International Scientific Advisory Board proudly present the 4th Edition of the Federation’s most prestigious and renowned publication, the TIF Guidelines For The Management…

Read. Learn. Empower. The Thalassaemia International Federation´s internationally acclaimed Educational Programme is a fundamental component of TIF´s work and is specifically designed for and addressed to the ever-growing learning needs…

Agios Pharmaceuticals, Inc. announced that it has submitted a New Drug Application (NDA) for Mitapivat to the U.S. Food and Drug Administration (FDA) for the treatment of adults with pyruvate…

TIF is excited to be participating in the 26th EHA Annual Congress, held this year virtually on 09 – 17 June 2021. Ms Lily Cannon, TIF Operations Manager, attended a…